The EPO has been observed to improve quality of life and adherence to PIFN/RBV treatment while lessening the need for RBV dose reductions in patients developing anaemia on combination therapy.8 Still, other studies have yielded conflicting results as to the impact of EPO on SVR.47, 48 It should be underscored that EPO is not approved by the FDA for use in combination with PIFN/RBV. Here, EPO is linked to anemia (phenotype).